WallStreetZenWallStreetZen

NYSEMKT: ASXC
Asensus Surgical Inc Stock Forecast, Predictions & Price Target

Analyst price target for ASXC

Based on 1 analyst offering 12 month price targets for Asensus Surgical Inc.
Min Forecast
$0.35+40.56%
Avg Forecast
$0.35+40.56%
Max Forecast
$0.35+40.56%

Should I buy or sell ASXC stock?

Based on 1 analyst offering ratings for Asensus Surgical Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ASXC stock forecasts and price targets.

ASXC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-04

1 of 1

Forecast return on equity

Is ASXC forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.5%

Forecast return on assets

Is ASXC forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

ASXC revenue forecast

What is ASXC's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$14.3M+66.61%
Avg 2 year Forecast
$31.5M+267.49%
Avg 3 year Forecast
$51.4M+499.04%
ASXC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ASXC revenue growth forecast

How is ASXC forecast to perform vs Medical Devices companies and vs the US market?
Company
81.1%
Industry
8.28%
Market
10.16%
ASXC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ASXC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ASXC vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
ASXC$0.25$0.35+40.56%Hold
ELUT$2.87$6.00+109.35%Strong Buy
MGRM$2.27N/AN/A
NVNO$5.50N/AN/A
HYPR$0.82$1.43+73.99%Hold

Asensus Surgical Stock Forecast FAQ

Is Asensus Surgical Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: ASXC) stock is to Hold ASXC stock.

Out of 1 analyst, 0 (0%) are recommending ASXC as a Strong Buy, 0 (0%) are recommending ASXC as a Buy, 1 (100%) are recommending ASXC as a Hold, 0 (0%) are recommending ASXC as a Sell, and 0 (0%) are recommending ASXC as a Strong Sell.

If you're new to stock investing, here's how to buy Asensus Surgical stock.

What is ASXC's revenue growth forecast for 2024-2026?

(NYSEMKT: ASXC) Asensus Surgical's forecast annual revenue growth rate of 81.1% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.28%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.16%.

Asensus Surgical's revenue in 2024 is $8,577,000.On average, 1 Wall Street analysts forecast ASXC's revenue for 2024 to be $3,886,685,213, with the lowest ASXC revenue forecast at $3,886,685,213, and the highest ASXC revenue forecast at $3,886,685,213. On average, 1 Wall Street analysts forecast ASXC's revenue for 2025 to be $8,573,010,351, with the lowest ASXC revenue forecast at $8,573,010,351, and the highest ASXC revenue forecast at $8,573,010,351.

In 2026, ASXC is forecast to generate $13,974,659,639 in revenue, with the lowest revenue forecast at $13,974,659,639 and the highest revenue forecast at $13,974,659,639.

What is ASXC's forecast return on assets (ROA) for 2024-2027?

(NYSEMKT: ASXC) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of N/A.

What is ASXC's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ASXC price target, the average ASXC price target is $0.35, with the highest ASXC stock price forecast at $0.35 and the lowest ASXC stock price forecast at $0.35.

The Wall Street analyst predicted that Asensus Surgical's share price could reach $0.35 by Apr 4, 2025. The average Asensus Surgical stock price prediction forecasts a potential upside of 40.56% from the current ASXC share price of $0.25.

What is ASXC's forecast return on equity (ROE) for 2024-2027?

(NYSEMKT: ASXC) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.